As life expectancy continues to rise, research is focusing increasingly on improving the quality of life of individuals, particularly the geriatric population. As blockbuster pharmacological breakthroughs become more expensive and even more elusive, the research environment is also changing. This has been evident in recent years in the pharmaceutical industry as well as in academic institutions where the rationalization and internationalization of research and development activities have manifested as major restructuring and development of collaborative associations.